Accueil › Leucémie aiguë myéloïde › Minnesota › Minneapolis
Essais cliniques pour Leucémie aiguë myéloïde à Minneapolis, MN
20 études pour Leucémie aiguë myéloïde recherchent des participants dans et autour de Minneapolis (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · à 5 mi
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · à 5 mi
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Recrutement en coursPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · à 5 mi
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Recrutement en coursPhase 1
- University of Minnesota/Masonic Cancer Center, Minneapolis
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · à 5 mi
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · à 5 mi
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Recrutement en coursPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · à 5 mi
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Recrutement en coursPhase 3
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Recrutement en coursPhase 1/2
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Recrutement en coursPhase 3
- Masonic Cancer Center, Minneapolis
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Recrutement en coursPhase 3
- University of Minnesota, Minneapolis
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Recrutement en coursPhase 1/2
- Masonic Cancer Center, Minneapolis
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Recrutement en coursPhase 1
- Masonic Cancer Center, Minneapolis
Allo HSCT Using RIC and PTCy for Hematological Diseases
Recrutement en coursPhase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Recrutement en coursPhase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Recrutement en coursPhase 1/2
- Mark Juckett, MD, Minneapolis
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Recrutement en coursPhase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
Recrutement en coursÉtude observationnelle
- University of Minnesota/Masonic Cancer Center, Minneapolis
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Recrutement en coursPhase 2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Recrutement en coursPhase 1
- University of Minnesota, Minneapolis
Essais pour Leucémie aiguë myéloïde dans d'autres villes
- Houston, TX85 études
- New York City, NY51 études
- Boston, MA44 études
- Baldwin Park, CA40 études
- Seattle, WA40 études
- Columbus, OH35 études
- Philadelphia, PA34 études
- Durham, NC33 études
- Atlanta, GA30 études
- Tampa, FL29 études
- Chicago, IL26 études
- Portland, OR25 études
Autres études à Minneapolis
- Cancer du sein27 études
- Cancer du poumon non à petites cellules26 études
- Cancer de l'ovaire24 études
- Cancer de la prostate23 études
- Cancer (tous types)22 études
- Insuffisance cardiaque21 études
- Cancer du poumon20 études
- Cancer colorectal19 études
- Cancer de l'endomètre18 études
- Maladie de Parkinson17 études
- Maladie cardiovasculaire15 études
- Maladie coronarienne13 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.